Centrose Board of Advisors

Dr. Wilson is President, Chief Executive Officer and a co-founder of Intellikine, a drug development company focused on lipid kinase inhibitors. He was formerly co-founder and Chief Business Officer at Ambrx, a biotechnology company focused on the optimization of therapeutic proteins using non-natural amino acids, as well as a co-founder of Wildcat, a start-up company focused on discovery of novel materials for industrial applications. Dr. Wilson was previously Vice President, Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation in San Diego, where his responsibilities included oversight of all business development, licensing, legal and intellectual property functions of the Institute. While at GNF, he was involved in the creation and launch of three spinout companies - Kalypsys, Phenomix, and Syrrx. Dr. Wilson obtained his Ph.D. in bioorganic chemistry from the University of California , Berkeley and his J.D. from New York University.

Dr. Molly Schmid has years of business and scientific experience in small to mid size biotechnology companies. She is currently a Professor at the Keck Graduate Institute of Applied Life Sciences where her work focuses on the business and science aspects of drug discovery and development. Prior to the Keck Institute, Professor Schmid spent ten years in the biotechnology industry, most recently as Senior Vice President of Preclinical Programs at Affinium Pharmaceuticals in Toronto, Ontario. Previously, she held positions as Senior Director, Functional Genomics & Bioinformatics at Genencor International (Palo Alto CA), and Vice President, Research Alliances at Microcide Pharmaceuticals (Mountain View CA). From 1986-1994, she was Assistant Professor of Molecular Biology at Princeton University. She is a Fellow of the American Academy of Microbiology, a Searle/Chicago Community Trust Scholar and a Damon Runyon-Walter Winchell Fellow. She received her Ph.D. in Biology from the University of Utah, and her B.S. from SUNY Albany.

Paul Anderson is a retired pharmaceutical industry expert; former VP at Bristol-Myers Squibb, VP of Chemistry at Merck's West Point, PA facility, and senior VP for DuPont Pharmaceuticals. He has been involved in research leading to the approved drugs Zocor, Trusopt, Aggrastat, Crixivan and Sustiva. Dr. Anderson is the 2006 Priestley Medalist, the highest honor granted by the American Chemical Society. He is also the recipient of numerous awards including the E.B. Hershberg Award for important discoveries in medicinally active substances. He was named the 2002 recipient of the Perkin Medal; the highest honor given for outstanding applied Chemistry in the United States. Dr. Anderson obtained B.S. in Chemistry from the University of Vermont and Ph.D. in Chemistry from the University of New Hampshire.

Dr. Pearce recently retired from Lilly Research Laboratories where he served as Vice President of Cancer Research and Clinical Investigation and Distinguished Research Fellow. Dr. Pearce has more than 27 years of experience in cancer drug discovery and was involved in the development of more than 25 investigational drugs which entered clinical trials for cancer, of which three have resulted in regulatory approvals and others are still in development. These drugs, which include Gemzar and Alimta, achieved 2007 combined worldwide sales exceeding $2 billion. His work included the use of natural products as models to identify new leads for cancer drug discovery and new efforts to probe mechanisms of drug resistance. He has been a consultant to the National Cancer Institute and the American Cancer Society and is a member of the editorial board of the Journal Molecular Cancer Therapeutics. Dr. Pearce received his Ph.D. in chemistry from Harvard.

Dr. Joe Bertino is Associate Director of the Cancer Institute of New Jersey and Professor of Medicine and Pharmacology at Robert Wood Johnson School of Medicine. He is most noted for his work in novel treatments for cancer patients and has published over 400 scientific articles. Dr. Bertino was the founding editor of the Journal of Clinical Oncology. Prior to his current positions, Dr. Bertino was Chairman of the Program of Molecular Pharmacology and Therapeutics at Memorial Sloan-Kettering Cancer Center and Director of the Yale Comprehensive Cancer Center.

Ed Sausville is the Associate Director for Clinical Research of the University of Maryland Cancer Center. He is also Professor of Medicine in the University of Maryland School of Medicine.  His work focuses on the elucidation of the molecular mechanism of novel therapeutic agents, signal transduction modulators for cancer treatment, and early phase clinical trials of new drugs for cancer treatment. Prior to Maryland, Dr. Suasville was Associate Director of the Division of Cancer Treatment and Diagnosis directing the NCI’s preclinical anti-cancer drug development portfolio, from screening studies through formulation, manufacture, and safety testing. Dr. Sausville received his undergraduate degree from Manhattan College and his Ph.D. and M.D. from the Albert Einstein College of Medicine.